Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Piazza Umberto I, 1, 70121 Bari BA, Italy
Commentary
Empagliflozin's Novel Cardioprotective Mechanism in Non-Diabetic Myocardial Infarction with Acute Hyperglycemyocardial Infarction
Author(s): Arundhati Guru*
Individuals who experienced both acute myocardial infarction and hyperglycaemic myocardial infarction upon admission to the hospital had a worse
prognosis than those who did not. The ability of sodium-glucose co-transporter-2 myocardial infarction inhibitors to treat acute hyperglycaemic
myocardial infarction and the underlying processes remains unknown. When non-diabetic myocardial infarction caused by a glucose injection cooccurred
with acute hyperglycaemic myocardial infarction in WT myocardial infarction. The survival rate was lower than in the control group. After
using empagliflozin, a notable improvement in LV function and survival was seen. Also, when a myocardial infarction was coupled with an acute
hyperglycaemic myocardial infarction, empagliflozin decreased fibrosis and autophagy of border cardiac tissue... Read More»
DOI:
10.37421/2475-3211.2023.8.202
Journal of Diabetic Complications & Medicine received 102 citations as per Google Scholar report